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Currently, the main available treatments for benign prostate hyperplasia (BPH) are alpha-1 adrenergic receptor 
antagonists (ARAs), 5-alpha reductase inhibitors (5-αRI), anticholinergics, and Phosphodiesterase-5 inhibitors. 
Recent studies support the combined therapy approach using ARAs with 5-αRI for lower urinary tract symptoms 
(LUTS) in BPH patients at risk of clinical progression. We aimed to review BPH management in select group of 
randomized controlled trials by combination therapy with ARAs and 5-αRIs compared to monotherapy with 
either drug with respect to the safety and efficacy. A total of 6 randomized controlled trials (RCTs) involving 
comparison of combination therapy with monotherapy using ARAs and 5-αRIs were retrieved from PubMed 
Central and reviewed for international prostate symptom score (IPSS), quality of life (QoL), post-residual urinary 
flow rate (PUF), and clinical progression. The results significantly favour the treatment group that received the 
combination therapy in comparison with the groups receiving monotherapy. However, outcome with regard to 
prostate volume showed insignificant improvement when the combination therapy is compared with 5- αRIs 
alone, rather than ARAs. In conclusion, combination therapy using ARAs and 5-αRI is better than monotherapy in 
the patients of BPH. Fixed dose combination (FDC), a type of combination, is also cost-effective and its side- 
effects profile resembles to that of monotherapy.   
1. Introduction 
Benign prostatic hyperplasia (BPH) is a common pathological con-
dition of the aging men. It affects over 50% of men by the age of 50 and 
above and its prevalence increases further with the advancing age (Lim, 
2017). It results from a non-cancerous enlargement of the prostate gland 
that is accompanied by multiple complications, including the lower 
urinary tract symptoms (LUTS), i.e., frequency, urgency, hesitancy, 
intermittency, and weak stream (Speakman and Cheng, 2014). The 
other risk factors, both modifiable and non-modifiable, that augment the 
risk of development as well as progression of BPH, besides others, 
include racial and genetic predisposition (Chughtai et al., 2016; Parsons, 
2007). Genome-wise association study has revealed genetic correlation 
with serum levels of prostatic serum antigen (Gudmundsson et al., 
2018). Aging incurs altered homeostasis due to physiological changes 
encompassing hormonal dysregulation to elevated oxidative stress that 
directly or indirectly impacts the prostate enlargement (Wen et al., 
2015). Loeb et al. have reported a median increase of 0.6 ml in a pros-
tatic volume that equals 2.5% growth in prostate size that included 278 
patients (mean age  58 years) (Loeb et al., 2009). On the same not, a 
recent study involving 40 patients (mean age  64 years) with symp-
tomatic BPH (PSA<10 ng/ml PSA) has shown a significant but weak 
positive correlation between age and PSA and prostate volume (Deori 
et al., 2017) Besides aging, components of metabolic syndrome such as 
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glucose intolerance, dyslipidaemia, hypertension, central obesity, and 
insulin resistance have been well-correlated with BPH relevant LUTS 
and IPSS (Lloyd et al., 2019; Sebastianelli and Gacci, 2018). Even though 
the average annual increase in total prostatic volume (TPV) is signifi-
cantly higher in patients with metabolic syndrome elements, the rela-
tionship between metabolic syndrome and BPH might be only due to 
similarity in the sex hormones profile (Rastrelli et al., 2019). 
2. Pathophysiology 
The enlargement of the prostate is central to both BPH development 
and progression, which is characterized by hyperplastic process that sets 
in the peri-urethral region thus causing an increase in the cell size and 
number in the epithelial and stromal tissue (Lee and Kuo, 2017). These 
cellular-level changes culminate in increased prostatic intra-urethral 
pressure, as well as prostatic urethral resistance, thus developing into 
LUTS and symptomatic BPH. Although the underlying cause of hyper-
plasia remains less well-understood, the role of androgens and inflam-
mation has been extensively studied in this regard (Bostanci et al., 2013; 
Wen et al., 2015). Dihydrotestosterone (DHT), a derivative of testos-
terone by the action of 5-α reductase type-2, is the principal prostate 
androgen that accounts for 90% of the total prostatic androgens (Carson 
and Rittmaster, 2003). It is pertinent to mention that unlike prostate 
growth during puberty, which is attributed to the increased levels of 
testosterone; prostate growth in the aged men is associated with low 
testosterone levels (Jarvis et al., 2015). These contriving observations 
disprove 5α-reductase inhibitor (5α-RI) as the standard treatment option 
for BPH. While 5α-RI effectively shrink the prostate volume, it is 
attributed to a decrease in DHT levels which remain elevated even in the 
presence of low testosterone levels in BPH patients. 
Besides the role of age and androgens, the presence of inflammatory 
cells, pro-inflammatory cytokines, and C-reactive protein support the 
development and progression of BPH (Fibbi et al., 2010). At the mo-
lecular level, AR activation and increased levels of reactive oxygen 
species (ROS) due to hypoxia developed from increased oxygen demand 
sets-in the inflammatory process (Vital et al., 2016). The inflammatory 
process may cause acute infection, which is then maintained beyond the 
acute phase into a chronic inflammatory phase (Kruslin et al., 2017). 
Mechanistically, the infiltrating Th1 cells secrete INF-γ and IL-2 during 
the early stages of BPH to stimulate the prostate stromal cells to produce 
IL-15 that leads to chronic inflammation which is dominated by Th2 and 
is characterized by elevated IL-4 and IL-13 levels thus characterizing the 
late stages of BPH. Also, IL-17 is found in BPH tissue which suggests a 
shift toward Th17 that speculates an autoimmune basis (Lloyd et al., 
2019). Interestingly, a novel biomarker JM-27 also increases in clini-
cally symptomatic BPH (Bechis et al., 2014). A serum-based enzyme--
linked immunosorbent assay (ELISA) has been developed to measure 
serum levels of JM-27 to delineate symptomatic and asymptomatic BPH 
patients (Bechis et al., 2014). 
According to the recently published molecular profiling, two bio-
logically distinct BPH subtypes have been identified, which were 
referred to as BPH-A subgroup and BPH-B subgroup (Liu et al., 2020). 
While BPH-A subtype is characterised by stromal-tissue-like features, 
BPH-B subtype has specific dysregulations involving metabolic path-
ways in the patients with obesity (BMI>30) and hypertension. Abnormal 
metabolism is also reported in BPH-A subgroup when compared to 
age-matched control samples (Liu et al., 2020; Tomlins et al., 2007). 
BPH-A subtype has been correlated with mTOR inhibition in 50% of the 
nominated sample of BPH-A subgroup and has been investigated as a 
potential therapeutic option for BPH patients (Fingar et al., 2002; 
Tumaneng et al., 2012). 
Contrary to the hypothesis that AR (androgen receptor) activation 
leads to vicious cycle of hypoxia and chronic inflammation, signalling 
disruption and subsequent downregulation of AR transduction cascade 
have been reported but the results get confounded by the exposure to 
medications affecting AR (Fenner, 2016; Zhang et al., 2016). 
Transcriptional analysis further identified KRAS gene signalling inacti-
vation, bone morphogenic protein 5 (BMP5) upregulation, and DNA 
hypermethylation, all disproving BPH as a neoplastic disease (Keszei 
et al., 2014; Kohler et al., 2012). KRAS gene signals the cells to mature, 
proliferate and differentiate and has been linked to multiple neoplastic 
processes (Keszei et al., 2014; Kohler et al., 2012). In addition, epige-
netic analysis revealed that DNA hypomethylation was globally found in 
neoplastic diseases, whereas BPH epigenetic landscape has been domi-
nated by DNA hypermethylation (Ehrlich, 2002; Jiang et al., 2008). 
3. Diagnosis and diagnosis evaluation 
The diagnosis of symptomatic BPH is generally based on the physical 
examination which reveals a diffusely enlarged, firm, and non-tender 
prostate supported by the storage and voiding symptoms (McConnell 
et al., 1994). Differential diagnosis of BPH includes urethral strictures, 
bladder neck contracture, prostate cancer, urinary tract infection, and 
neurogenic bladder. The criterion for clinical evaluation of BPH has 
been developed by the Agency for Health Care Policy and Research and 
updated by the American Urologic Association (AUA) in 2010 and 2019 
(Deters et al., 2019; McVary et al., 2010; Nickel et al., 2010). AUA/In-
ternational Prostate Symptom Score (AUA/IPSS) assesses the severity of 
symptoms and requires the patient to respond to seven questions, i.e., 
frequency, nocturia, weak urinary stream, hesitancy, intermittency, 
incomplete emptying, and urgency. The score ranges from 0 to 5 (NOT 
present to almost ALWAYS present). This score aids in patients’ symp-
toms classification from mild (total score 0–7) to moderate (8–19), and 
severe (20–35) (Barry et al., 1992). Besides urologic conditions and 
symptoms, the history of patient about general health (i.e. diabetes 
mellitus is a BPH risk factor), family history about BPH or prostate 
cancer, and pharmacological history are important (Pearson and Wil-
liams, 2014). 
A digital rectal examination assesses prostate size and consistency 
although the information about prostate size is unreliable until it should 
be large enough, i.e., >50 g to be recognized. A tender prostate is 
generally indicative of prostatitis while nodules are alarming for ma-
lignant transformation. Laboratory findings supportive in BPH diagnosis 
includes urine analysis, serum creatinine, and the detection of Prostate- 
specific antigen (PSA) in the patient’s serum samples. While urine 
analysis also is important for differential diagnosis of urinary tract 
infection (Nickel et al., 2010) and serum creatinine is part of the routine 
assessment for BPH, PSA levels in the serum screens the patients for 
prostate cancer especially in patients between the ages of 50–69 years. 
Some of the additional tests include urine cytology, post-void residual 
urine volume, and urethral cystoscopy. 
4. Management of BPH patients 
The management of BPH patients includes recommendations for 
lifestyle changes, pharmacological intervention and in the advanced 
cases with complications, it may necessitate surgical intervention. 
Lifestyle changes and watchful waiting without any pharmacological 
intervention is recommended for patients who have mild symptoms 
(IPSS  7), in addition to annual visits and evaluation of the patient 
history to see if there are any indications to start medication (Sarma and 
Wei, 2012). Similarly, advanced BPH necessitates surgical intervention 
that primarily involves transurethral resection of the prostate (TURP) or 
minimally invasive laparoscopic/robotic simple prostatectomy, and 
Holmium Laser Enucleation of the Prostate (HoLEP) (Williams et al., 
2013). Please also see recent advances and guidelines by AUA, 2019 
(Foster et al., 2018). 
Advances in pharmacological management overtime have consider-
ably reduced the rate of surgical intervention for BPH (Presicce et al., 
2017). The contemporary approach of monotherapy (IMM) is generally 
employed to address lower urinary tract symptoms with drugs belonging 
to various pharmacological groups including ARAs, 5-alpha reductase 
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inhibitors (5-αRIs), anticholinergic agents, and phosphodiesterase-5 
inhibitors (PDE5I). Treatment with ARAs generally suffices for pa-
tients with mild (IPSS  7) to moderate (IPSS 8–19) BPH. 
4.1. Alpha-1 blockers (Alpha-1 adrenergic receptor antagonists) 
Drugs from this group are the most commonly prescribed for BPH 
patient to relieve their lower urinary track-related symptoms. Treatment 
with ARAs relaxes the smooth muscle tone in the bladder neck to 
decrease the resistance along the bladder neck and prostate, thus facil-
itating the flow of urine. Treatment with ARAs decreases 4–6 points in 
the IPSS (Emberton et al., 2008). Drugs in this group may be 
non-selective ARAs (i.e., phenoxybenzamine), selective short-acting 
ARAs (i.e., prazosin, alfuzosin, and indoramin), selective long-acting 
ARAs (i.e., terazosin, doxazosin, and slow-release (SR) alfuzosin), and 
partially subtype (ARA-1a)–selective agents (i.e., tamsulosin, and silo-
dosin) (Emberton et al., 2008; McVary et al., 2010). As the non-selective 
group shows an adverse side-effect profile i.e., drowsiness, depression, 
dizziness, dry mouth, ejaculatory failure, extrapyramidal signs, nasal 
congestion, and weight gain, it is out of clinical practice per current 
guidelines (McVary et al., 2010). On the contrary, the selective group 
specifically interacts with either of the receptor subtypes a, b, and c 
using respective ARAs. 
Originally designed as anti-hypertensive agent, naftopidil has been 
used for the management of BPH symptom (Hara et al., 2013), Subse-
quent to the earlier reported success in the clinical studies (Yasuda et al., 
1994; Yokoyama et al., 2006), Masumori et el., reported a three-year 
follow-up in a prospective study in 117 BPH patients who were 
treated with naftopidil (50 mg or 75 mg per day) (Masumori et al., 
2016). The patients were aged 50 years and above were having IPSS 
score of 8 or more. A total of 25% patients successfully continued the 
medication 5-αRIs for three years. The results of the study showed 
long-term efficacy of the treatment; however, the beneficial effects were 
limited by older age, increased prostate volume and higher-level PSA at 
the start of the treatment. The same group has earlier published a 5-year 
follow-up data from a prospective study to show that monotherapy with 
ARA tamsulosin might not be appropriate for patients with a large 
prostate and high post-void residual urine volume. Nevertheless, 
symptomatic improvement continued despite stopping tamsulosin 
therapy in young patients (Masumori et al., 2013). 
4.2. 5α-reductase inhibitor (5α-RI) 
Two of the prototype drugs of this group, i.e., finasteride and 
dutasteride are particularly efficient in patients with enlarged prostate 
besides LUTS (McVary et al., 2010). The mechanism of action of 5α-RI is 
through approximately 80% reduction of testosterone conversion to 
DHT. This leads to a reduction in DHT concentration, which otherwise 
accumulates in prostate cells and is considered as responsible for pros-
tate enlargement (Kim et al., 2018). The typical side-effects of 5α-RI 
include decreased libido, erectile dysfunction (ED), and ejaculation 
disorder as reported by long-term trial of finasteride versus placebo in 
30–40 men with BPH (Wessells et al., 2003). Moreover, breast 
enlargement (gynecomastia), breast tenderness, general rash, and anx-
iety have also been reported (McConnell et al., 1998). With use of 5a-RI 
especially for periods longer than 4 years, the incidence of sexual 
adverse effects generally decreases with longer duration of therapy 
(Corona et al., 2017; Debruyne et al., 2004). Comorbidity status which is 
frequently correlated with elderly population, may adversely increase 
the risk of developing erectile dysfunction (ED) with 5a-RI inhibitor 
therapy (Fusco et al., 2015). although the exact underlying molecular 
mechanism remains less well-elucidated. However, it is generally 
attributed to decreased synthesis of neurotransmitters by 5ARI leading 
to reduced sexual desire and possible penile fibrosis due to cholinergic 
and nitrergic supra-sensitivity thus resulting in anatomical and physio-
logical degeneration of penile tissue (Gur et al., 2013). 
Additionally, 5α-RI has teratogenic potential (Traish et al., 2014). 
Treatment with 5α-RI for six months also causes up to 50% reduction in 
PSA with an associated shrinkage of prostate mass (Bell et al., 2009). 
Data from 2 RCTs showed that treatment with 5α-RI significantly 
reduced the incidence of prostatic cancer but may enhance the risk of 
high-grade prostatic cancer (McConnell et al., 1998). Although 5α-RI 
can reduce the volume of prostate in most patients, about one fourth 
(25%) of patients do not show any improvement and can experience 
worsening of their symptoms (Bechis et al., 2014). ARAs appear to be 
more effective than 5-αRIs for short- and long-term management of BPH. 
In a meta-analysis comparing ARAs monotherapy with 5α-RIs, dox-
azosin and terazosin were better in the management of urinary symp-
toms as compared to finasteride (Tacklind et al., 2010). 
Table 1 
The table summarizes in a chronological order the studies reviewed for combination therapy of BPH in terms of the aim, methodology, and results of each trial briefly.   
Objective Methods Results 
Debruyne et al. 
(1998) 
Study of the effects of combined 
treatment with alfuzosin & 
finasteride. 
The study was double-blind, randomized, and 
multicenter trial involving 1051 BPH patients with 
LUTS. 
Reduction in IPSS was highest in alfuzosin group, followed by 
combination & finasteride groups. At end point of study, 
results were comparable in all groups. 
McConnell et al. 
(2003) 
Study the long-term effects of 
doxazosin, finasteride 
&combination therapy. 
Double-blind, long-term trial with a mean follow-up 
of 4.5 years; 3047 patients. Primary outcome assessed 
by Intention to Treat analysis. 
Significant reduction in AUR, UI, UTI of doxazosin (39% RR) & 
finasteride (34% RR) vs placebo. Reduction with combined 
therapy (66% vs placebo) was more than monotherapy. 
Roehrborn et al. 
(2008) 
Comparing dutasteride, 
tamsulosin, & their combined 
therapy. 
Multicenter, randomized, double-blind, parallel 
group study in BPH patients >50 years. LUTS & PUF 
assessed every 3 & 6 months respectively for 2 years. 
Combination therapy has significantly greater improvements 
in symptoms when compared to dutasteride from month 3, and 
tamsulosin from month 9. 
Montorsi et al. 
(2011) 
Comparing dutasteride & 
tamsulosin monotherapy vs 
combination therapy. 
Multicenter, Double-blind, parallel-group study; 4844 
patients aged 50 years; prostate volume of 30 ml, 
4 years duration. 
At 4-years, mean reduction in storage and voiding symptoms 
sub-scores was significantly more in combination therapy as 
compared to monotherapy except for dutasteride when 
prostate volume is > 58 ml. 
Roehrborn et al. 
(2015) 
Efficacy and safety of FDC of 
dutasteride & tamsulosin vs 
tamsulosin monotherapy. 
Multicenter, randomized, open-label trial; 742 men 
with an IPSS of 8–19, Prostate volume >30 ml, and 
total serum PSA >1.5 ml. 
Significant reduction for FDC vs control group (  5.4 vs   3.6 
points, P < 0.001). FDC had a 43.1% (P < 0.001) reduction in 
risk of progression. Similar safety profile as monotherapy with 
each drug. 
Shrestha and 
Karmacharya 
(2015) 
Analyzing the usefulness of 
combination therapy of 
finasteride & tamsulosin. 
92 patients randomized into two groups (combined 
therapy tamsulosin  finasteride group and 
monotherapy with only Tamsulosin). 
RV significantly reduced with combined therapy more than 
monotherapy. The sample of this study is smaller than other 
studies and have also proved its effectiveness. 
List of Abbreviations: AUA American urological association; AUR  acute urinary retention; UI  urinary incontinence; UTI  urinary tract infection; BPH  benign 
prostate hyperplasia; FDC  fixed dose combination; IPPS  international prostate symptom score; PSA  prostate specific antigen; PUF  peak urinary flow; RR  Risk 
reduction; RV  residual volume. 
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4.3. Anti-cholinergic agents 
Anticholinergics, i.e., flavoxate, propiverine, and oxybutynin, etc. 
serve as an alternative therapy for patients presenting largely with 
symptoms such as frequency, urgency, and incontinence related with the 
overactivity of detrusor muscle however without elevated post-void 
residual volume. Overactivity of detrusor is reported in virtually 40%– 
70% of patients with bladder outlet obstruction. Given the propensity of 
muscarinic receptor in the bladder smooth muscle, anticholinergics are 
an obvious choice for intervention in such patients. Although the use of 
anticholinergics is considered safe, their use in patients with BPH having 
LUTS is not without their side-effects (Blake-James et al., 2007). How-
ever, side-effects such as dry mouth, blurry vision, constipation, 
drowsiness, sedation, and possibility of acute retention of urine have 
allowed only limited use in BPH patients (Athanasopoulos et al., 2008). 
Combined therapy using anticholinergics with ARAs to treat LUTS 
symptoms in BPH patients has shown encouraging results in terms of 
safety and efficacy (Kim et al., 2017; Pang et al., 2016). 
4.4. Phosphodiesterase-5 (PDE-5) inhibitors 
Phosphodiesterase (PDE) is a superfamily of enzymes with extensive 
distribution in various body tissues including the prostate and bladder 
(Lin et al., 2013). The selectivity of PDE5 for cGMP makes it an attrac-
tive intracellular target to promote cGMP second messenger activity for 
various therapeutic benefits including cell survival, proliferation and 
cellular protection (Haider et al., 2010; Li et al., 2012). Inhibition of 
PDE-5 using PDE5 inhibitors allows vasodilation and relaxation of the 
smooth muscle that has been exploited for the treatment of BPH patients 
(Giuliano et al., 2013). The only approved PDE-5 inhibitor for the 
management of BPH is tadalafil (Gacci et al., 2013). However, its use is 
not without side-effects that include back pain, dyspepsia, headache, 
limb pain, myalgia, nausea, and flushing. Of note, tadalafil can be used 
either alone or combined with the 5-αRIs, i.e., finasteride, in patients 
with BPH/LUTS and erectile dysfunction (Olesovsky and Kapoor, 2016). 
5. A combinatorial approach to treat BPH 
A combined therapy approach using drugs from each group exploits 
the best of their unique mechanism of action. It allows interference with 
the disease process by simultaneous exploitation of a two-pronged 
strategy. The safety and effectiveness of the combinatorial approach 
have been extensively studied in randomized control trials some of 
which have been enlisted in Table-1. We have analyzed the data from 6 
RCTs which was retrieved from the Advanced PubMed Search engine, 
using the terms: ((prostatic hyperplasia) AND (therapy) AND (combi-
nation)) and applying the filter (Clinical Trials) in the sidebar. However, 
we did not include all the published trials as it was beyond the scope of 
our mini-review. Our analysis plan for each RCT was to read the text 
thoroughly, describe the population, type of intervention and control 
groups, randomization process, the settings of the trial, and then 
cautiously analysing the results and report the conclusions. 
According to the latest guidelines of the AUA, a combinatorial 
treatment approach based on ARAs and 5α-RI would be more effective 
for the treatment of patients with LUTS and enlarged prostate than their 
individual use (Foster et al., 2018). Hence, the FDA approved formula-
tion of Jalyn containing 0.4 g tamsulosin, and 0.5 dutasteride is more 
effective in providing symptomatic relief to the BPH patients than either 
of the two drugs used alone (Dimitropoulos and Gravas, 2016) and 
successfully improve IPSS (Madersbacher et al., 2007). While mono-
therapy with ARAs alleviates BPH-associated LUTS symptoms by 
maximizing urinary flow rate, 5α-RI treatment shrinks prostate size 
(McVary, 2007). 
European ALFIN study group (1998) assessed the additive benefits of 
combining alfuzosin and finasteride in 1051 patients with LUTS due to 
BPH (Debruyne et al., 1998). The patients were randomized into three 
treatment groups including alfuzosin (n  358), finasteride (n  344), 
and combined treatment (n  349) groups. The primary end-points of 
the study were improvement in IPSS and Maximum Flow Rate (Qmax), 
while the safety of the combined treatment was monitored by the re-
ported adverse events. The treatment was continued for 6 months. The 
results in the three treatment groups showed symptomatic improvement 
insignificantly differing between the alfuzosin group and the combina-
tion treatment group in the first month. On the contrary, the finasteride 
treatment group significantly trailed behind the two groups with only 
33% of patients showing a 50% improvement. Similarly, in the overall 
population, increases in Qmax were significantly larger with alfuzosin 
treatment and the combined treatment groups as compared to finaste-
ride alone after 1 month of therapy. It was evident from the data that 
combination treatment using alfuzosin and finasteride did not offer a 
significantly higher benefit to the patients as compared to alfuzosin 
alone. 
A subsequent study by McConnell et al. (2003) conducted a 
multi-centered double blinded clinical trial Medical Therapy of Prostatic 
Symptoms (MTOPS) (McConnell et al., 2003). The study was designed to 
ascertain the beneficial effects combined treatment of BPH patients with 
doxazosin and finasteride in 3047 patients out of the total 4391 patients 
who were initially screened for the study. The average follow-up time 
duration for the patients was 4.5 years. The patients were randomized to 
receive their respective treatment using placebo-treated patients as a 
control. The drug treatment groups included doxazosin, finasteride, and 
combination therapy groups (n  756 patients per group). The primary 
outcomes of the study were clinical progression of the disease which was 
defined as an increase of four points above the baseline of AUA symptom 
score, AUR, UI, and recurrent UTI) was assessed using ITT analysis. The 
assessment of the patients and their data were kept blinded. The data 
showed a significant risk reduction in the measures of the primary 
outcome in doxazosin (39%, P < 0.001), finasteride (34%, P  0.002), 
and combination therapy (66%, P < 0.001) in comparison with the 
placebo treatment group (McConnell et al., 2003). The data thus 
generated evidenced the long-term safety and effectiveness of the 
combinatorial pharmacological intervention as a superior option as 
compared to monotherapy. 
Roehrborn et al. (2008) compared dutasteride, tamsulosin, and their 
combination for the treatment of LUTS in men with BPH and prostate 
enlargement (Roehrborn et al., 2008). Sponsored by GlaxoSmithKline, 
the CombAT study (ClinicalTrials.gov Identifier: NCT00090103) was a 
multi-centered, double-blind, randomized, parallel group study per-
formed in 503 centers. A total of 4844 men aged 50 and older were 
enrolled in the study. According to the Inclusion criteria set up for the 
study, participants had an IPSS of 12 or greater, a prostatic volume of 30 
ml or greater, serum PSA 1.5–10 ng/ml, and PUF 5 ml–15 ml per second. 
The participants were randomized to receive dutasteride, tamsulosin or 
combination therapy and were followed-up for 4 years (Roehrborn et al., 
2010). The primary outcome data published at 2 years of daily treatment 
showed a significant change in IPSS from baseline. The combination 
therapy resulted in significant improvement in the symptoms when 
compared to dutasteride from month 3, and tamsulosin from month 9. 
The change from baseline post-residual urinary flow-rate showed sig-
nificant improvement in the combination group as compared to both 
monotherapy groups after 6-months of treatment. However, the rate of 
adverse drug reactions was significantly increased in the combined 
treatment group as compared to the monotherapy treated patients. The 
results from the 4-year follow-up revealed the safety and effectiveness of 
the combinatorial approach although the study lacked a placebo-treated 
group of patients (Roehrborn et al., 2010). Montorsi et al. (2011) 
analyzed the mean changes of the storage and voiding symptoms at 4 
years as compared to their baseline values in the sub-scales of IPSS pa-
tients (Montorsi et al., 2011). The results showed a mean reduction both 
in the storage and voiding symptoms in the combination treatment 
group as compared to the monotherapy groups of patients (P < 0.001). 
Nevertheless, patients with a baseline prostate volume of more than 58 
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ml failed to benefit from the combined therapy as compared with 
monotherapy with dutasteride. These observations show the limitations 
of the combined therapy approach in patients for baseline prostate size 
(Montorsi et al., 2011). 
Subsequently, the same group assessed the safety and efficacy of a 
fixed-dose combined (FDC) administration of dutasteride and tamsulo-
sin treatment (Duodart®) for the management of men with moderately 
symptomatic BPH at risk of progression. The study was a multi-centered, 
randomized open-label trial conducted in 742 men with an IPSS of 8–19, 
the prostate volume of more than 30 ml, and total serum PSA of more 
than 1.5 ml (Roehrborn et al., 2015). The primary outcome was a 
symptomatic improvement from baseline to 24 months that was 
measured by IPSS. Therapeutic benefits in the FDC administration group 
were significantly more as compared to the control group taking tam-
sulosin alone. For example, the FDC administration group showed 
43.1% (P < 0.001) risk reduction in the progression as compared to the 
control group. The safety profile of FDC administration was consistent 
with the profiles of dutasteride and tamsulosin as monotherapy 
(Roehrborn et al., 2015). These data support that the FDC administra-
tion of dutasteride and tamsulosin along with lifestyle changes leads to 
continued and therapeutically stable improvement in men with mod-
erate BPH at risk of progression and significantly reduced risk of BPH 
progression. 
Sherestha et al. (2015) used a combination of tamsulosin with fi-
nasteride to treat benign prostate enlargement (Shrestha and Karma-
charya, 2015). The primary aim of the study was to ascertain the 
usefulness of combined therapy with finasteride and tamsulosin in 
comparison with monotherapy with each of the two drugs. The study 
included men aged 45 and above (n  92) and diagnosed with BPH. The 
patients were grouped equally to receive combination therapy or mon-
otherapy with tamsulosin once daily at bedtime. AUA symptom score 
decreased significantly in the combination therapy group of patients (P 
< 0.0001) as compared to tamsulosin treated group with a concomitant 
reduction in residual volume with combination therapy as compared to 
the monotherapy treatment (P < 0.0001 vs. P  0.1271). These data 
validated the findings of the prior studies to conclude that combination 
therapy is more effective in decreasing LUTS as compared to the mon-
otherapy treatment strategy. 
6. Discussion and conclusion 
Unlike to the earlier trials had found that combined treatment of 
ARAs and 5-αRIs therapy was not superior to monotherapy with an ARAs 
(Debruyne et al., 1998), subsequent randomized trials have demon-
strated the benefits of long-term use of combination therapy (Montorsi 
et al., 2011; Roehrborn et al., 2008). Nearly 84% of the articles we 
reviewed favoured dual therapy over monotherapy while the remaining 
16% showed that monotherapy with some drugs like alfuzosin has 
comparable results with combination therapy. As inclusion criteria 
require a prostatic volume of equal to or more than 30 ml in the par-
ticipants, the results show that efficacy of such comparison may be only 
specific to a certain population of BPH patients. Besides being phar-
macologically more effective, combination therapy is more cost effective 
as compared the monotherapy. Walker et al. (2013) have reported the 
long-term cost-effectiveness of single-dose of dutasteride and tamsulosin 
combination therapy as a first-line treatment for BPH from the 
perspective of the UK National Health Service and concluded that 
combination therapy has a higher probability of being cost-effective as 
compared to either monotherapy and compared with the two therapies 
taken separately (Walker et al., 2013). 
Secondary outcomes on side-effect profile of dual therapy showed 
that patients mostly suffered from sexual dysfunction (e.g. decreased 
ejaculation, erectile dysfunction, etc.), which was comparable to that of 
monotherapy, suggesting no significant difference. In conclusion, com-
bined treatment with ARAs and 5-αRIs has been the most widely 
investigated combination for BPH which shows that the approach is safe, 
more efficacious and cost-effective as compared to the monotherapy. 
The data support the inference that it causes significant reduction in 
IPSS (Figure-1), improvement in Qol, and other subjective and objective 
measures of BPH suggesting a synergistic effect of the drug combination, 
especially in patients who have a moderate enlargement of the prostate 
(prostate volume <30 ml). With excellent long-term outcomes, combi-
nation therapy can be started as soon as patients are found to have 
prostate enlargement causing moderate to severe symptoms. 
Authors contributions 
Conceptualization: OZ, AF, MM, MH. Data curation: OZ, AF, MM, 
Fig. 1. Mean reduction in IPSS score with combination therapy (grey bar) as compared to 5-alpha reductase inhibitor alone (orange bar), and alpha-1 blockers alone 
(blue bar). Only Debruyne et al., 1998 shows that alpha1 blocker resulted in a more marked reduction in IPSS score compared to combination therapy. Nevertheless, 
combination therapy shows a fairly greater reduction in IPSS score in the other studies with at least 2-years of follow up. (For interpretation of the references to 
colour in this figure legend, the reader is referred to the Web version of this article.) 
O.A. Zitoun et al.                                                                                                                                                                                                                               
European Journal of Pharmacology 883 (2020) 173301
6
MH. Methodology and Formal Analysis: OZ, AF, MM, BA, KH. Resources: 
OZ, AF, MM, MH, BA, KH. Supervision and Validation: BA, KH. Visu-
alization: OZ, AF, MM, KH. Writing – original draft: OZ, AF, MM, MH, 
KH. Writing – review & editing: OZ, AF, MM, MH, BA, KH. 
Funding 
This research did not receive any specific grant from funding 
agencies in the public, commercial, or not-for-profit sectors. 
Compliance with ethical standards 
Research involving human participants and/or animals 
This article does not contain any studies with human participants or 
animals performed by any of the authors. 
Informed consent 
Not applicable. 
Declaration of competing interest 
The authors have nothing to disclose. 
Acknowledgement 
Not applicable. 
References 
Athanasopoulos, A., Mitropoulos, D., Giannitsas, K., Perimenis, P., 2008. Safety of 
anticholinergics in patients with benign prostatic hyperplasia. Expet Opin. Drug Saf. 
https://doi.org/10.1517/14740338.7.4.473. 
Barry, M.J., Fowler, F.J., O’Leary, M.P., Bruskewitz, R.C., Holtgrewe, H.L., Mebust, W.K., 
Cockett, A.T., 1992. The American urological association symptom index for benign 
prostatic hyperplasia. The measurement committee of the American urological 
association. J. Urol. 148, 1549–1557 discussion 1564.  
Bechis, S.K., Otsetov, A.G., Ge, R., Olumi, A.F., 2014. Personalized medicine for the 
management of benign prostatic hyperplasia. J. Urol. https://doi.org/10.1016/j. 
juro.2014.01.114. 
Bell, C.M., Hatch, W.V., Fischer, H.D., Cernat, G., Paterson, J.M., Gruneir, A., Gill, S.S., 
Bronskill, S.E., Anderson, G.M., Rochon, P.A., 2009. Association between tamsulosin 
and serious ophthalmic adverse events in older men following cataract surgery. 
JAMA, J. Am. Med. Assoc. 301 https://doi.org/10.1001/jama.2009.683, 
1991–1996.  
Blake-James, B.T., Rashidian, A., Ikeda, Y., Emberton, M., 2007. The role of 
anticholinergics in men with lower urinary tract symptoms suggestive of benign 
prostatic hyperplasia: a systematic review and meta-analysis. BJU Int. https://doi. 
org/10.1111/j.1464-410X.2006.06574.x. 
Bostanci, Y., Kazzazi, A., Momtahen, S., Laze, J., Djavan, B., 2013. Correlation between 
benign prostatic hyperplasia and inflammation. Curr. Opin. Urol. https://doi.org/ 
10.1097/MOU.0b013e32835abd4a. 
Carson, C., Rittmaster, R., 2003. The role of dihydrotestosterone in benign prostatic 
hyperplasia. Urology. https://doi.org/10.1016/S0090-4295(03)00045-1. 
Chughtai, B., Forde, J.C., Thomas, D.D.M., Laor, L., Hossack, T., Woo, H.H., Te, A.E., 
Kaplan, S.A., 2016. Benign prostatic hyperplasia. Nat. Rev. Dis. Prim. 2, 1–15. 
https://doi.org/10.1038/nrdp.2016.31. 
Corona, G., Tirabassi, G., Santi, D., Maseroli, E., Gacci, M., Dicuio, M., Sforza, A., 
Mannucci, E., Maggi, M., 2017. Sexual dysfunction in subjects treated with inhibitors 
of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta- 
analysis. Andrology. https://doi.org/10.1111/andr.12353. 
Debruyne, F., Barkin, J., Erps, P., Van Reis, M., Tammela, T.L.J., Roehrborn, C., 2004. 
Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor 
dutasteride in men with symptomatic benign prostatic hyperplasia. Eur. Urol. 46, 
488–495. https://doi.org/10.1016/j.eururo.2004.05.008. 
Debruyne, F.M.J., Jardin, A., Colloi, D., Resel, L., Witjes, W.P.J., Delauche-Cavallier, M. 
C., McCarthy, C., Geffriaud-Ricouard, C., 1998. Sustained-release alfuzosin, 
finasteride and the combination of both in the treatment of benign prostatic 
hyperplasia. Eur. Urol. 34, 169–175. https://doi.org/10.1159/000019706. 
Deori, R., Das, B., Abdur Rahman, M., 2017. A study of relationship of prostate volume, 
prostate specific antigen and age in benign prostatic hyperplasia. Int. J. Contemp. 
Med. Res. 4, 1582–1586. 
Deters, L.A., Costabile, R.A., Leveillee, R.J., Moore, C.R., Patel, V.R., 2019. Benign 
prostatic hyperplasia (BPH) guidelines [WWW document], accessed 5.16.20. 
https://emedicine.medscape.com/article/437359-guidelines. 
Dimitropoulos, K., Gravas, S., 2016. Fixed-dose combination therapy with dutasteride 
and tamsulosin in the management of benign prostatic hyperplasia. Ther. Adv. Urol. 
https://doi.org/10.1177/1756287215607419. 
Ehrlich, M., 2002. DNA methylation in cancer: too much, but also too little. Oncogene. 
https://doi.org/10.1038/sj.onc.1205651. 
Emberton, M., Cornel, E.B., Bassi, P.F., Fourcade, R.O., Gomez, J.M.F., Castro, R., 2008. 
Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and 
options for medical management. Int. J. Clin. Pract. https://doi.org/10.1111/j.1742- 
1241.2008.01785.x. 
Fenner, A., 2016. BPH: disrupting AR signalling promotes inflammation. Nat. Rev. Urol. 
https://doi.org/10.1038/nrurol.2016.187. 
Fibbi, B., Penna, G., Morelli, A., Adorini, L., Maggi, M., 2010. Chronic inflammation in 
the pathogenesis of benign prostatic hyperplasia. Int. J. Androl. https://doi.org/ 
10.1111/j.1365-2605.2009.00972.x. 
Fingar, D.C., Salama, S., Tsou, C., Harlow, E., Blenis, J., 2002. Mammalian cell size is 
controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 
16, 1472–1487. https://doi.org/10.1101/gad.995802. 
Foster, H.E., Barry, M.J., Dahm, P., Gandhi, M.C., Kaplan, S.A., Kohler, T.S., Lerner, L.B., 
Lightner, D.J., Parsons, J.K., Roehrborn, C.G., Welliver, C., Wilt, T.J., McVary, K.T., 
2018 Sep. Surgical management of lower urinary tract symptoms attributed to 
benign prostatic hyperplasia: AUA guideline. J. Urol. 200 (3), 612–619. https://doi. 
org/10.1016/j.juro.2018.05.048. 
Fusco, F., Arcaniolo, D., Creta, M., Piccinocchi, G., Arpino, G., Laringe, M., 
Piccinocchi, R., Longo, N., Verze, P., Mangiapia, F., Imperatore, V., Mirone, V., 2015. 
Demographic and comorbidity profile of patients with lower urinary tract symptoms 
suggestive of benign prostatic hyperplasia in a real-life clinical setting: are 5-alpha- 
reductase inhibitor consumers different? World J. Urol. 33, 685–689. https://doi. 
org/10.1007/s00345-014-1460-9. 
Gacci, M., Sebastianelli, A., Salvi, M., Vignozzi, L., Corona, G., McVary, K.T., Kaplan, S. 
A., Oelke, M., Maggi, M., Carini, M., 2013. PDE5-Is for the treatment of concomitant 
ED and LUTS/BPH. Curr. Bladder Dysfunct. Rep. https://doi.org/10.1007/s11884- 
013-0184-9. 
Giuliano, F., Ückert, S., Maggi, M., Birder, L., Kissel, J., Viktrup, L., 2013. The 
mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower 
urinary tract symptoms related to benign prostatic hyperplasia. Eur. Urol. https:// 
doi.org/10.1016/j.eururo.2012.09.006. 
Gudmundsson, J., Sigurdsson, J.K., Stefansdottir, L., Agnarsson, B.A., Isaksson, H.J., 
Stefansson, O.A., Gudjonsson, S.A., Gudbjartsson, D.F., Masson, G., Frigge, M.L., 
Stacey, S.N., Sulem, P., Halldorsson, G.H., Tragante, V., Holm, H., Eyjolfsson, G.I., 
Sigurdardottir, O., Olafsson, I., Jonsson, T., Jonsson, E., Barkardottir, R.B., 
Hilmarsson, R., Asselbergs, F.W., Geirsson, G., Thorsteinsdottir, U., Rafnar, T., 
Thorleifsson, G., Stefansson, K., 2018. Genome-wide associations for benign 
prostatic hyperplasia reveal a genetic correlation with serum levels of PSA. Nat. 
Commun. 9, 1–8. https://doi.org/10.1038/s41467-018-06920-9. 
Gur, S., Kadowitz, P.J., Hellstrom, W.J., 2013. Effects of 5-Alpha reductase inhibitors on 
erectile function, sexual desire and ejaculation. Expet Opin. Drug Saf. https://doi. 
org/10.1517/14740338.2013.742885. 
Haider, H.K., Lee, Y.J., Jiang, S., Ahmed, R.P.H., Ryon, M., Ashraf, M., 2010. 
Phosphodiesterase inhibition with tadalafil provides longer and sustained protection 
of stem cells. Am. J. Physiol. Heart Circ. Physiol. 299 https://doi.org/10.1152/ 
ajpheart.00437.2010. 
Hara, N., Mizusawa, T., Obara, K., Takahashi, K., 2013. The role of naftopidil in the 
management of benign prostatic hyperplasia. Ther. Adv. Urol. https://doi.org/ 
10.1177/1756287212461681. 
Jarvis, T.R., Chughtai, B., Kaplan, S.A., 2015. Testosterone and benign prostatic 
hyperplasia. Asian J. Androl. https://doi.org/10.4103/1008-682X.140966. 
Jiang, L., Gonda, T.A., Gamble, M.V., Salas, M., Seshan, V., Tu, S., Twaddell, W.S., 
Hegyi, P., Lazar, G., Steele, I., Varro, A., Wang, T.C., Tycko, B., 2008. Global 
hypomethylation of genomic DNA in cancer-associated myofibroblasts. Can. Res. 68, 
9900–9908. https://doi.org/10.1158/0008-5472.CAN-08-1319. 
Keszei, A.F.A., Tang, X., McCormick, C., Zeqiraj, E., Rohde, J.R., Tyers, M., Sicheri, F., 
2014. Structure of an SspH1-PKN1 complex reveals the basis for host substrate 
recognition and mechanism of activation for a bacterial E3 ubiquitin ligase. Mol. Cell 
Biol. 34, 362–373. https://doi.org/10.1128/mcb.01360-13. 
Kim, E.H., Brockman, J.A., Andriole, G.L., 2018. The use of 5-alpha reductase inhibitors 
in the treatment of benign prostatic hyperplasia. Asian J. Urol. https://doi.org/ 
10.1016/j.ajur.2017.11.005. 
Kim, H.J., Sun, H.Y., Choi, H., Park, J.Y., Bae, J.H., Doo, S.W., Yang, W.J., Song, Y.S., 
Ko, Y.M., Kim, J.H., 2017. Efficacy and safety of initial combination treatment of an 
alpha blocker with an anticholinergic medication in benign prostatic hyperplasia 
patients with lower urinary tract symptoms: updated meta-analysis. PloS One 12. 
https://doi.org/10.1371/journal.pone.0169248. 
Kohler, J., Erlenkamp, G., Eberlin, A., Rumpf, T., Slynko, I., Metzger, E., Schüle, R., 
Sippl, W., Jung, M., 2012. Lestaurtinib inhibits histone phosphorylation and 
androgen-dependent gene expression in prostate cancer cells. PloS One 7. https:// 
doi.org/10.1371/journal.pone.0034973. 
Kruslin, B., Tomas, D., Dzombeta, T., Milkovic-Perisa, M., Ulamec, M., 2017. 
Inflammation in prostatic hyperplasia and carcinoma-basic scientific approach. 
Front. Oncol. 7 https://doi.org/10.3389/fonc.2017.00077. 
Lee, C.L., Kuo, H.C., 2017. Pathophysiology of benign prostate enlargement and lower 
urinary tract symptoms: current concepts. Tzu Chi Med. J. https://doi.org/10.4103/ 
tcmj.tcmj_20_17. 
Li, L., Haider, H.K., Wang, L., Lu, G., Ashraf, M., 2012. Adenoviral short hairpin RNA 
therapy targeting phosphodiesterase 5a relieves cardiac remodeling and dysfunction 
following myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 302 https://doi. 
org/10.1152/ajpheart.00339.2011. 
O.A. Zitoun et al.                                                                                                                                                                                                                               
European Journal of Pharmacology 883 (2020) 173301
7
Lim, K. Bin, 2017. Epidemiology of clinical benign prostatic hyperplasia. Asian J. Urol. 
https://doi.org/10.1016/j.ajur.2017.06.004. 
Lin, C.S., Albersen, M., Xin, Z., Namiki, M., Muller, D., Lue, T.F., 2013. 
Phosphodiesterase-5 expression and function in the lower urinary tract: a critical 
review. Urology. https://doi.org/10.1016/j.urology.2012.11.028. 
Liu, D., Shoag, J.E., Poliak, D., Goueli, R.S., Ravikumar, V., Redmond, D., Vosoughi, A., 
Fontugne, J., Pan, H., Lee, D., Thomas, D., Salari, K., Wang, Z., Romanel, A., Te, A., 
Lee, R., Chughtai, B., Olumi, A.F., Mosquera, J.M., Demichelis, F., Elemento, O., 
Rubin, M.A., Sboner, A., Barbieri, C.E., 2020. Integrative multiplatform molecular 
profiling of benign prostatic hyperplasia identifies distinct subtypes. Nat. Commun. 
11 https://doi.org/10.1038/s41467-020-15913-6. 
Lloyd, G.L., Marks, J.M., Ricke, W.A., 2019. Benign prostatic hyperplasia and lower 
urinary tract symptoms: what is the role and significance of inflammation? Curr. 
Urol. Rep. https://doi.org/10.1007/s11934-019-0917-1. 
Loeb, S., Kettermann, A., Carter, H.B., Ferrucci, L., Metter, E.J., Walsh, P.C., 2009. 
Prostate volume changes over time: results from the baltimore longitudinal study of 
aging. J. Urol. 182, 1458–1462. https://doi.org/10.1016/j.juro.2009.06.047. 
Madersbacher, S., Marszalek, M., Lackner, J., Berger, P., Schatzl, G., 2007. The long-term 
outcome of medical therapy for BPH. Eur. Urol. https://doi.org/10.1016/j. 
eururo.2007.03.034. 
Masumori, N., Tsukamoto, T., Horita, H., Sunaoshi, K. ichi, Tanaka, Y., Takeyama, K., 
Sato, E., Miyao, N., 2013. α1-blocker tamsulosin as initial treatment for patients with 
benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter 
study. Int. J. Urol. 20, 421–428. https://doi.org/10.1111/j.1442-2042.2012.03165. 
x. 
Masumori, N., Tsukamoto, T., Shibuya, A., Miyao, N., Kunishima, Y., Iwasawa, A., 2016. 
Three-year outcome analysis of alpha 1-blocker naftopidil for patients with benign 
prostatic hyperplasia in a prospective multicenter study in Japan. Patient Prefer. 
Adherence 10, 1309–1316. https://doi.org/10.2147/PPA.S110440. 
McConnell, J.D., Barry, M.J., Bruskewitz, R.C., 1994. Benign prostatic hyperplasia: 
diagnosis and treatment. Agency for health Care policy and research. Clin. Pract. 
Guidel. Quick Ref. Guide Clin. 1–17. 
McConnell, J.D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Logan Holtgrewe, H., 
Albertsen, P., Roehrborn, C.G., Nickel, J.C., Wang, D.Z., Taylor, A.M., 
Waldstreicher, J., 1998. The effect of finasteride on the risk of acute urinary 
retention and the need for surgical treatment among men with benign prostatic 
hyperplasia. N. Engl. J. Med. 338, 557–563. https://doi.org/10.1056/ 
NEJM199802263380901. 
McConnell, J.D., Roehrborn, C.G., Bautista, O.M., Andriole, G.L., Dixon, C.M., Kusek, J. 
W., Lepor, H., McVary, K.T., Nyberg, L.M., Clarke, H.S., Crawford, E.D., Diokno, A., 
Foley, J.P., Foster, H.E., Jacobs, S.C., Kaplan, S.A., Kreder, K.J., Lieber, M.M., 
Lucia, M.S., Miller, G.J., Menon, M., Milam, D.F., Ramsdell, J.W., Schenkman, N.S., 
Slawin, K.M., Smith, J.A., 2003. The long-term effect of doxazosin, finasteride, and 
combination therapy on the clinical progression of benign prostatic hyperplasia. 
N. Engl. J. Med. 349, 2387–2398. https://doi.org/10.1056/NEJMoa030656. 
McVary, K.T., 2007. A review of combination therapy in patients with benign prostatic 
hyperplasia. Clin. Therapeut. 29, 387–398. https://doi.org/10.1016/S0149-2918 
(07)80077-4. 
McVary, K.T., Roehrborn, C.G., Avins, A.L., Barry, M.J., Bruskewitz, R.C., Donnell, R.F., 
Foster, H.E., Gonzalez, C.M., Kaplan, S.A., Penson, D.F., Ulchaker, J.C., Wei, J.T., 
2010. American urological association guideline: management of benign prostatic 
hyperplasia. Am. Urol. Assoc. 
Montorsi, F., Roehrborn, C., Garcia-Penit, J., Borre, M., Roeleveld, T.A., Alimi, J.C., 
Gagnier, P., Wilson, T.H., 2011. The effects of dutasteride or tamsulosin alone and in 
combination on storage and voiding symptoms in men with lower urinary tract 
symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the 
Combination of Avodart and Tamsulosin (CombA. BJU Int. 107, 1426–1431. https:// 
doi.org/10.1111/j.1464-410X.2011.10129.x. 
Nickel, J.C., Mendez-Probst, C.E., Whelan, T.F., Paterson, R.F., Razvi, H., 2010. 2010 
update: guidelines for the management of benign prostatic hyperplasia. J. Can. Urol. 
Assoc. 4, 310–316. https://doi.org/10.5489/cuaj.10124. 
Olesovsky, C., Kapoor, A., 2016. Evidence for the efficacy and safety of tadalafil and 
finasteride in combination for the treatment of lower urinary tract symptoms and 
erectile dysfunction in men with benign prostatic hyperplasia. Ther. Adv. Urol. 
https://doi.org/10.1177/1756287216650132. 
Pang, R., Zhou, X.Y., Wang, X. ling, Wang, B., Yin, X.L., Bo, H., 2016. Anticholinergics 
combined with alpha-blockers for treating lower urinary tract symptoms related to 
benign prostatic obstruction. Cochrane Database Syst. Rev. https://doi.org/ 
10.1002/14651858.CD012336, 2016.  
Parsons, J.K., 2007. Modifiable risk factors for benign prostatic hyperplasia and lower 
urinary tract symptoms: new approaches to old problems. J. Urol. https://doi.org/ 
10.1016/j.juro.2007.03.103. 
Pearson, R., Williams, P.M., 2014. Common questions about the diagnosis and 
management of benign prostatic hyperplasia. Am. Fam. Physician 90, 769–774. 
Presicce, F., De Nunzio, C., Tubaro, A., 2017. Can long-term LUTS/BPH pharmacological 
treatment alter the outcomes of surgical intervention? Curr. Urol. Rep. https://doi. 
org/10.1007/s11934-017-0721-8. 
Rastrelli, G., Vignozzi, L., Corona, G., Maggi, M., 2019. Testosterone and benign prostatic 
hyperplasia. Sex. Med. Rev. https://doi.org/10.1016/j.sxmr.2018.10.006. 
Roehrborn, C.G., Oyarzabal Perez, I., Roos, E.P.M., Calomfirescu, N., Brotherton, B., 
Wang, F., Palacios, J.M., Vasylyev, A., Manyak, M.J., 2015. Efficacy and safety of a 
fixed-dose combination of dutasteride and tamsulosin treatment (Duodart®) 
compared with watchful waiting with initiation of tamsulosin therapy if symptoms 
do not improve, both provided with lifestyle advice, in the management. BJU Int. 
116, 450–459. https://doi.org/10.1111/bju.13033. 
Roehrborn, C.G., Siami, P., Barkin, J., Dami~ao, R., Major-Walker, K., Morrill, B., 
Montorsi, F., 2008. The effects of dutasteride, tamsulosin and combination therapy 
on lower urinary tract symptoms in men with benign prostatic hyperplasia and 
prostatic enlargement: 2-year results from the CombAT study. J. Urol. 179, 616–621. 
https://doi.org/10.1016/j.juro.2007.09.084. 
Roehrborn, C.G., Siami, P., Barkin, J., Dami~ao, R., Major-Walker, K., Nandy, I., 
Morrill, B.B., Gagnier, R.P., Montorsi, F., 2010. The effects of combination therapy 
with dutasteride and tamsulosin on clinical outcomes in men with symptomatic 
benign prostatic hyperplasia: 4-year results from the CombAT study. Eur. Urol. 57, 
123–131. https://doi.org/10.1016/j.eururo.2009.09.035. 
Sarma, A.V., Wei, J.T., 2012. Benign prostatic hyperplasia and lower urinary tract 
symptoms. N. Engl. J. Med. 367, 248–257. https://doi.org/10.1056/ 
NEJMcp1106637. 
Sebastianelli, A., Gacci, M., 2018. Current status of the relationship between metabolic 
syndrome and lower urinary tract symptoms. Eur. Urol. Focus. https://doi.org/ 
10.1016/j.euf.2018.03.007. 
Shrestha, B.B., Karmacharya, M., 2015. Finasteride and tamsulosin combination in 
benign prostatic enlargement in a tertiary hospital. JNMA. J. Nepal Med. Assoc. 53, 
1–4. 
Speakman, M.J., Cheng, X., 2014. Management of the complications of BPH/BOO. In: 
Indian Journal of Urology. Medknow Publications, pp. 208–213. https://doi.org/ 
10.4103/0970-1591.127856. 
Tacklind, J., Fink, H.A., Macdonald, R., Rutks, I., Wilt, T.J., 2010. Finasteride for benign 
prostatic hyperplasia. Cochrane Database Syst. Rev. https://doi.org/10.1002/ 
14651858.CD006015.pub3. 
Tomlins, S.A., Mehra, R., Rhodes, D.R., Cao, X., Wang, L., Dhanasekaran, S.M., Kalyana- 
Sundaram, S., Wei, J.T., Rubin, M.A., Pienta, K.J., Shah, R.B., Chinnaiyan, A.M., 
2007. Integrative molecular concept modeling of prostate cancer progression. Nat. 
Genet. 39, 41–51. https://doi.org/10.1038/ng1935. 
Traish, A.M., Mulgaonkar, A., Giordano, N., 2014. The dark side of 5α-reductase 
inhibitors’ therapy: sexual dysfunction, high gleason grade prostate cancer and 
depression. Korean J. Urol. https://doi.org/10.4111/kju.2014.55.6.367. 
Tumaneng, K., Russell, R.C., Guan, K.L., 2012. Organ size control by Hippo and TOR 
pathways. Curr. Biol. https://doi.org/10.1016/j.cub.2012.03.003. 
Vital, P., Castro, P., Ittmann, M., 2016. Oxidative stress promotes benign prostatic 
hyperplasia. Prostate 76, 58–67. https://doi.org/10.1002/pros.23100. 
Walker, A., Doyle, S., Posnett, J., Hunjan, M., 2013. Cost-effectiveness of single-dose 
tamsulosin and dutasteride combination therapy compared with tamsulosin 
monotherapy in patients with benign prostatic hyperplasia in the UK. BJU Int. 112, 
638–646. https://doi.org/10.1111/j.1464-410X.2012.11659.x. 
Wen, S., Chang, H.C., Tian, J., Shang, Z., Niu, Y., Chang, C., 2015. Stromal androgen 
receptor roles in the development of normal prostate, benign prostate hyperplasia, 
and prostate cancer. Am. J. Pathol. https://doi.org/10.1016/j.ajpath.2014.10.012. 
Wessells, H., Roy, J., Bannow, J., Grayhack, J., Matsumoto, A.M., Tenover, L., 
Herlihy, R., Fitch, W., Labasky, R., Auerbach, S., Parra, R., Rajfer, J., Culbertson, J., 
Lee, M., Bach, M.A., Waldstreicher, J., 2003. Incidence and severity of sexual 
adverse experiences in finasteride and placebo-treated men with benign prostatic 
hyperplasia. Gold J. Urol. 61, 579–584. https://doi.org/10.1016/S0090-4295(02) 
02401-9. 
Williams, N., Bulstrode, C., O’Connell, P.R., 2013. The prostate and seminal vesicles. In: 
Bailey & Love’s Short Practice of Surgery. CRC Press, pp. 1347–1350. 
Yasuda, K., Yamanishi, T., Tojo, M., Nagashima, K., Akimoto, S., Shimazaki, J., 1994. 
Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: 
assessment by urodynamic studies. Prostate 25, 46–52. https://doi.org/10.1002/ 
pros.2990250107. 
Yokoyama, T., Kumon, H., Nasu, Y., Takamoto, H., Watanabe, T., 2006. Comparison of 
25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with 
benign prostatic hyperplasia: a prospective, randomized controlled study. Int. J. 
Urol. 13, 932–938. https://doi.org/10.1111/j.1442-2042.2006.01443.x. 
Zhang, B., Kwon, O.J., Henry, G., Malewska, A., Wei, X., Zhang, L., Brinkley, W., 
Zhang, Y., Castro, P.D., Titus, M., Chen, R., Sayeeduddin, M., Raj, G.V., Mauck, R., 
Roehrborn, C., Creighton, C.J., Strand, D.W., Ittmann, M.M., Xin, L., 2016. Non-cell- 
autonomous regulation of prostate epithelial homeostasis by androgen receptor. 
Mol. Cell 63, 976–989. https://doi.org/10.1016/j.molcel.2016.07.025. 
O.A. Zitoun et al.                                                                                                                                                                                                                               
